Comment · Fri, April 24, 2015 · Ceretropic
cqnfw59
What they were answering
pseupseudio · 2 points
that little bit of research just generated a number of questions...
1. wiki says the company developing this has had some fits and starts with it, and have discovered that intranasal delivery causes high blood pressure but subcutaneous administration doesn't have that effect. i'm curious if you know how that would even be the case.
2. suppose you do develop and sell this as a research chemical, not for humans, etc. somewhere during this time, PT completes their trials, gets FDA approval to bring it to market and so on. what is the impact of this on you/your company's ability to offer this?
u/MisterYouAreSoDumb · Ceretropic
1) That is probably due to higher BBB permeation. Sub-Q will be more peripheral, and consequently not have the same central BP effects. That is just a guess, though. I will do some more research on it.
2) We'll have to cross that bridge if/when it happens. Some companies don't care about small players, where others like Neuralstem do.